Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-iPSMA
- Development stage
- Unknown
- Lead developer
- Instituto Nacional de Investigaciones Nucleares
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
64Cu-iPSMA (also known as 64Cu-NOTA-HYNIC-iPSMA) is a positron emission tomography (PET) radiopharmaceutical developed for the diagnostic imaging of prostate cancer. It consists of the iPSMA ligand, which has high affinity for prostate-specific membrane antigen (PSMA), conjugated to the bifunctional chelator NOTA (or DOTA) and radiolabeled with the positron-emitting isotope copper-64 (64Cu). PSMA is a transmembrane glycoprotein that is significantly overexpressed in prostate cancer cells, particularly in advanced and metastatic stages. Upon binding to PSMA, 64Cu-iPSMA is internalized into the cells, allowing for high-contrast PET imaging of prostate cancer lesions and metastases. The longer half-life of copper-64 (12.7 hours) compared to gallium-68 or fluorine-18 allows for delayed imaging timepoints, which can improve tumor-to-background ratios and facilitate dosimetry planning for theranostic applications.
- Other names
- 64Cu-DOTA-HYNIC-iPSMA64Cu-NOTA-Benzoyl-NCS-HYNIC-iPSMA64Cu-NOTA-HYNIC-iPSMA[64Cu]Cu-NOTA-HYNIC-iPSMA
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 64Cu-iPSMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-iPSMA.